AgomAb Therapeutics NV (NASDAQ:AGMB – Get Free Report) fell 5.9% during mid-day trading on Wednesday . The company traded as low as $13.80 and last traded at $13.98. 128,480 shares changed hands during trading, a decline of 2% from the average session volume of 130,966 shares. The stock had previously closed at $14.85.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the company. B. Riley Financial began coverage on AgomAb Therapeutics in a report on Thursday, July 23rd. They set a “buy” rating and a $34.00 target price on the stock. HC Wainwright initiated coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.00.
Check Out Our Latest Report on AgomAb Therapeutics
AgomAb Therapeutics Stock Performance
AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. As a group, sell-side analysts expect that AgomAb Therapeutics NV will post -1.73 EPS for the current year.
About AgomAb Therapeutics
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Featured Articles
- Five stocks we like better than AgomAb Therapeutics
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
- Intel’s Rally Gave It a $20 Billion Opportunity and Now Comes the Hard Part
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
